Researcher Tamura from DMPK & Safety Business Unit to Present a Poster at the 17th Annual Meeting of Japanese Safety Pharmacology Society

2026.02.17

Researcher Tamura from the DMPK & Safety Business Unit, will deliver a poster presentation at The 17th Annual Meeting of Japanese Safety Pharmacology Society, to be held in Omiya, Saitama in Japan.
If you plan to attend the conference, we encourage you to join the session and hear the presentation.

Conference Name: The 17th Annual Meeting of Japanese Safety Pharmacology Society

Date & Time: February 27, 2026, 13:40-14:40 (JST)

Location: Sonic City, Omiya, Saitama, Japan

Title: Applicability of Ca transient measurements in cardiotoxicity screening

Poster number: P-18

Presentation Summary
Predicting QT prolongation is essential for minimizing proarrhythmic risk during drug discovery and development. While the Comprehensive in Vitro Proarrhythmia Assay (CiPA) initiative recommends multi-electrode array (MEA) analysis using iPSC-derived cardiomyocytes, the practical application of this approach is constrained by the long testing period and substantial compound requirements.
In this study, we compared the sensitivity and specificity of Ca transient assay and MEA assay for detecting QT prolongation and early afterdepolarizations (EADs), using 28 CiPA reference compounds. Our results demonstrated that Ca transient assay provided higher sensitivity for QT prolongation and EAD detection, while lower specificity than the MEA assay. Ca transient assay can be completed in a shorter time and requires smaller amounts of test compound. These advantages support its suitability as a screening tool for evaluating proarrhythmic risk in the early stages of drug discovery.

Axcelead DDP’s Soulution
At Axcelead, we provide comprehensive in vitro safety screening services to support lead compound optimization. For cardiotoxicity assessments, we offer a wide range of evaluations tailored to the development stage of drug candidates, from ion channel current assays to QT risk assessments using hiPSC-derived cardiomyocytes. Please feel free to contact us for further information if you are considering cardiotoxicity assessment.